Heidelberg Pharma AG

Equities

HPHA

DE000A11QVV0

Biotechnology & Medical Research

Real-time Estimate Tradegate Other stock markets 09:53:43 2024-04-30 am EDT			5-day change	1st Jan Change
2.98 ^EUR	-0.67%		-2.92%	-20.05%

Apr. 25	Heidelberg Pharma AG Reports Earnings Results for the First Quarter Ended February 29, 2024	CI
Apr. 23	Transcript : Heidelberg Pharma AG - Special Call

DD: Heidelberg Pharma AG: Walter Miller, buy

April 17, 2024 at 03:26 am EDT

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

17.04.2024 / 09:23 CET/CEST
The issuer is solely responsible for the content of this announcement.

1. Details of the person discharging managerial responsibilities / person closely associated

a) Name

Title:
First name:	Walter
Last name(s):	Miller

2. Reason for the notification

a) Position / status

Position:

Member of the managing body

b) Initial notification

3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name

Heidelberg Pharma AG

b) LEI

391200E09XYBYITR1W32

4. Details of the transaction(s)

a) Description of the financial instrument, type of instrument, identification code

Type:	Share
ISIN:	DE000A11QVV0

b) Nature of the transaction

Acquisition

c) Price(s) and volume(s)

Price(s)	Volume(s)
3.0300 EUR	3030.00 EUR
3.0200 EUR	3020.00 EUR

d) Aggregated information

Price	Aggregated volume
3.0250 EUR	6050.0000 EUR

e) Date of the transaction

15/04/2024; UTC+2

f) Place of the transaction

Name:	Berlin Tradegate
MIC:	TGAT

17.04.2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

Language:	English
Company:	Heidelberg Pharma AG
	Gregor-Mendel-Str. 22
	68526 Ladenburg
	Germany
Internet:	www.heidelberg-pharma.com


End of News	EQS News Service

91051 17.04.2024 CET/CEST

Latest news about Heidelberg Pharma AG

Heidelberg Pharma AG Reports Earnings Results for the First Quarter Ended February 29, 2024	Apr. 24	CI
Transcript : Heidelberg Pharma AG - Special Call	Apr. 23
Heidelberg Pharma Wins US FDA Orphan Drug Designation for Multiple Myeloma Treatment	Mar. 27	MT
Transcript : Heidelberg Pharma AG, 2023 Earnings Call, Mar 25, 2024	Mar. 25
Heidelberg Pharma AG Reports Earnings Results for the Full Year Ended November 30, 2023	Mar. 24	CI
Heidelberg Pharma Concludes Royalty Purchase Deal with HealthCare Royalty	Mar. 19	MT
Heidelberg Pharma CEO to Retire; Chief Scientific Officer Named Successor	Nov. 29	MT
Heidelberg Pharma Unit Secures European Patent for Amanitin Toxin-Based Antibody-Drug Conjugates	Nov. 15	MT
Heidelberg Pharma AG Reports Earnings Results for the Nine Months Ended August 31, 2023	23-10-12	CI
Heidelberg Pharma Provides Update on Phase I/IIa Clinical Trial with Lead Candidate HDP-101	23-09-19	CI
Heidelberg Pharma Gets Milestone Payment for Antibody Technology	23-08-08	MT
Transcript : Heidelberg Pharma AG, H1 2023 Earnings Call, Jul 13, 2023	23-07-13
Heidelberg Pharma AG Reports Earnings Results for the Second Quarter and Six Months Ended May 31, 2023	23-07-13	CI
Heidelberg Pharma Ag Announces Executive Changes	23-05-08	CI
Germany's Heidelberg Pharma Appoints CFO	23-05-05	MT
Heidelberg Pharma AG Reports Earnings Results for the First Quarter Ended February 28, 2023	23-04-12	CI
Heidelberg Pharma AG Provides Earnings Guidance for the Year 2023	23-03-27	CI
Transcript : Heidelberg Pharma AG, 2022 Earnings Call, Mar 27, 2023	23-03-27
Heidelberg Pharma AG Reports Earnings Results for the Full Year Ended November 30, 2022	23-03-23	CI
Heidelberg Pharma AG Reports Earnings Results for the Full Year Ended November 30, 2022	23-03-23	CI
Heidelberg Pharma AG Auditor Raises 'Going Concern' Doubt	23-03-23	CI
Transcript : Heidelberg Pharma AG - Special Call	23-02-15
Heidelberg Pharma Signs Research and Exclusive Option Agreement with Binghamton University on Immunostimulatory Technology Platform	22-12-16	CI
Heidelberg Pharma Ag Announces Encouraging Clinical Data from Two Antibody Drug Conjugates Based on Heidelberg Pharma’s ATAC Technology	22-12-13	CI
Heidelberg Pharma AG Reports Earnings Results for the Nine Months Ended August 31, 2022	22-10-13	CI

Chart Heidelberg Pharma AG

Duration

Period

More charts

Company Profile

Heidelberg Pharma AG, formerly Wilex AG, is a Germany-based Company, which is engaged in the biopharmaceuticals sector. The Company focuses on the research and development of therapy treatments for oncology area. It aims at applying toxin Amanitin into cancer therapies using its Antibody Targeted Amanitin Conjugate (ATAC) technology. The Companyâs pipeline includes a number of drug candidates, such as HDP-101, a B-cell maturation antigen ATAC for multiple myeloma; PSMA-ATAC, prostate-specific membrane antigens, and CD19-ATAC, a B-lymphocyte antigen. Through partnerships, the Company develops clinical assets, including MESUPRON, REDECTANE and RENCAREX. It also offers preclinical contract research services.

Sector

Biotechnology & Medical Research

Calendar

2024-05-12 - PEGS Boston Conference

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3 EUR

Average target price

11.3 EUR

Spread / Average Target

+276.67%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
HEIDELBERG PHARMA AG	-20.05%	150M
VERTEX PHARMACEUTICALS INCORPORATED	-3.04%	102B
REGENERON PHARMACEUTICALS, INC.	+1.58%	96.29B
ARGENX SE	+2.07%	22.18B
BIONTECH SE	-15.61%	21.2B
GENMAB A/S	-9.21%	18.31B
WUXI APPTEC CO., LTD.	-38.74%	17.38B
BEIGENE, LTD.	-13.48%	16.36B
NEUROCRINE BIOSCIENCES, INC.	+6.12%	13.97B
SAREPTA THERAPEUTICS, INC.	+34.04%	12.17B

Bio Therapeutic Drugs